COCP News - Candlesense

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

(NASDAQ:COCP) BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a c...

Investor conference

8 days ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, ...

What is the implied breakeven point for the antiviral programs based on current cost structure and projected market size? Are there any non‑financial risks (e.g., legal, IP, manufacturing) mentioned that could affect the company's outlook? What is the historical performance of Cocrystal's stock around earnings releases and how does that inform expected price movement?

Earnings

28 days ago